These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18046919)

  • 1. Role of 5 alpha-reductase inhibitors in the management of prostate cancer.
    Hudak SJ; Hernandez J; Thompson IM
    Clin Interv Aging; 2006; 1(4):425-31. PubMed ID: 18046919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dutasteride and prostate cancer.
    Garattini S; Bertele' V
    N Engl J Med; 2010 Aug; 363(8):794; author reply 794-6. PubMed ID: 20842790
    [No Abstract]   [Full Text] [Related]  

  • 3. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice.
    Opoku-Acheampong AB; Unis D; Henningson JN; Beck AP; Lindshield BL
    PLoS One; 2013; 8(10):e77738. PubMed ID: 24204943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB; Parekh DJ
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of pivotal studies for prostate cancer risk reduction, past and present.
    Andriole GL
    Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: a serious disease suitable for prevention.
    Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
    BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
    Arena F
    Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention using dutasteride: the REDUCE trial.
    Gomella LG
    Curr Opin Urol; 2005 Jan; 15(1):29-32. PubMed ID: 15586026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
    MMW Fortschr Med; 2003 Feb; 145(9):54. PubMed ID: 12666533
    [No Abstract]   [Full Text] [Related]  

  • 12. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.
    Zong HT; Peng XX; Yang CC; Zhang Y
    Asian J Androl; 2011 Nov; 13(6):812-8. PubMed ID: 21892196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.
    Djavan B; Milani S; Fong YK
    Expert Opin Pharmacother; 2005 Feb; 6(2):311-7. PubMed ID: 15757426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer chemoprevention with 5α-reductase inhibitors.
    Nepple KG; Andriole GL
    Urol Oncol; 2012 Sep; 30(5):553-4. PubMed ID: 23193568
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical applications of five-alpha reductase inhibitors.
    Loughlin KR
    Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of 5-alpha-reductase inhibitors in the prevention of prostate cancer].
    Schulman C
    Ann Urol (Paris); 2004 Dec; 38 Suppl 2():S35-42. PubMed ID: 15651489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dutasteride: a review of its use in the management of prostate disorders.
    Keam SJ; Scott LJ
    Drugs; 2008; 68(4):463-85. PubMed ID: 18318566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
    Opoku-Acheampong AB; Nelsen MK; Unis D; Lindshield BL
    PLoS One; 2012; 7(1):e29068. PubMed ID: 22242155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of prostate cancer.
    Vemana G; Hamilton RJ; Andriole GL; Freedland SJ
    Annu Rev Med; 2014; 65():111-23. PubMed ID: 24188663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H; Kanetake H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.